Golan, Talia <br/><br/>
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.  [electronic resource] 

 -  Cancer medicine  Oct 2015 
 - 1472-83 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-7634 
<br/><br/><label>Standard No.: </label>10.1002/cam4.491  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anemia--chemically induced<br/>Antibiotics, Antineoplastic--administration & dosage<br/>Fatigue--chemically induced<br/>Female<br/>Humans<br/>Liposomes<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Mitomycin--administration & dosage<br/>Neoplasms--drug therapy<br/>Polyethylene Glycols<br/>Prodrugs--administration & dosage<br/>Response Evaluation Criteria in Solid Tumors<br/>Thrombocytopenia--chemically induced